Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China | Zendy

Zhong Liu | Zendy; Mingfang Ji | Zendy; Qianfang Huang | Zendy; Fang Fang | Zendy; Qiuyun Liu | Zendy; Wei-Hua Jia | Zendy; Xiaofang Guo | Zendy; Sisi Xie | Zendy; Fang Chen | Zendy; Yun Liu | Zendy; Hao Mo | Zendy; Weiye Liu | Zendy; Yi Yu | Zendy; W.-M. Cheng | Zendy; Y.-Y. Yang | Zendy; Binrui Wu | Zendy; Kuang Rong Wei | Zendy; Ling Wei | Zendy; Xiao Lin | Zendy; E.-H. Lin | Zendy; Weimin Ye | Zendy; Ming Hong | Zendy; YiXin Zeng | Zendy; S Cao | Zendy

Open Access

Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China

Author(s) -

Zhong Liu,

Mingfang Ji,

Qianfang Huang,

Fang Fang,

Qiuyun Liu,

Wei-Hua Jia,

Xiaofang Guo,

Sisi Xie,

Fang Chen,

Yun Liu,

Hao Mo,

Weiye Liu,

Yi Yu,

W.-M. Cheng,

Y.-Y. Yang,

Binrui Wu,

Kuang Rong Wei,

Ling Wei,

Xiao Lin,

E.-H. Lin,

Weimin Ye,

Ming Hong,

YiXin Zeng,

S Cao

Publication year - 2012

Publication title -

american journal of epidemiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.33

H-Index - 256

eISSN - 1476-6256

pISSN - 0002-9262

DOI - 10.1093/aje/kws404

Subject(s) - nasopharyngeal carcinoma , serology , medicine , virology , epstein–barr virus , cluster (spacecraft) , antibody , virus , oncology , immunology , radiation therapy , computer science , programming language

A nasopharyngeal carcinoma (NPC) mass screening trial using a combination of immunoglobulin A antibodies to Epstein-Barr virus capsid antigen and nuclear antigen-1 by enzyme-linked immunosorbent assay in addition to indirect mirror examination in the nasopharynx and/or lymphatic palpation (IMLP) was conducted in southern China. Cantonese aged 30-59 years residing in 2 cities randomly selected by cluster sampling, Sihui and Zhongshan, were invited to participate in this screening from May 2008 through May 2010. Participants were offered fiberoptic endoscopy examination and/or pathologic biopsy if their serologic tests reached our predefined level of high risk or if results from the physical examination indicated possible cancer (i.e., were IMLP positive). A total of 28,688 individuals were voluntarily screened in the initial round. The overall NPC detection rate was 0.14% (41/28,688) with an early diagnosis rate of 68.3% (28/41) during the first year of follow-up. Thirty-eight of 41 cases (92.7%) were detected among the high-risk group, and 7 of 41 cases (17.1%) were detected among the IMLP-positive group. The 2 Epstein-Barr virus serologic tests by enzyme-linked immunosorbent assay could be a feasible alternative for NPC screening in endemic areas. Further follow-up is needed to examine whether screening has an effect on decreasing mortality from NPC in these areas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research